NECTIN4 and urinary bladder cancer: Other promising therapeutic targets for bladder cancer include nectin-4, a cell surface protein that is overexpressed in most bladder cancer patients, and enfortumab vedotin, an antibody-drug conjugate that targets nectin-4 [1,3, 4-9].